Stay updated on Daratumumab Combo in MRD+ Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo in MRD+ Myeloma Clinical Trial page.

Latest updates to the Daratumumab Combo in MRD+ Myeloma Clinical Trial page
- Check6 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check13 days agoChange DetectedAdded related topics metadata: Multiple myeloma and MedlinePlus Genetics. This metadata helps with navigation and discovery without changing the study content.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded new trial sites in Detroit (Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion), Novant Health, and Temple University Hospital Jeanes Campus. Removed existing sites including Fox Chase Cancer Center and Henry Ford Cancer Institute.SummaryDifference0.4%

- Check35 days agoChange DetectedAdded related topic links for Multiple Myeloma and MedlinePlus Genetics and updated the page revision to v3.4.1; a government funding notice was removed. The study data, endpoints, and eligibility criteria remain unchanged.SummaryDifference0.3%

- Check42 days agoChange DetectedUpdated Pittsburgh locations: added site in ZIP 15232 and removed ZIP 15323. A government funding status notice was added to the page.SummaryDifference0.4%

- Check49 days agoChange DetectedAdded glossary and new page metadata (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and page Revision to v3.4.0) and removed older items (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Daratumumab Combo in MRD+ Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo in MRD+ Myeloma Clinical Trial page.